Physician profile
James D Byrum
NPI 1396703252
$1,262.83
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $968 · 2020: $195 · 2022: $11.71 · 2024: $88.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $88.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $88.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $169.85 | 2019-2020 | |
| Astellas Pharma US INC | $121.19 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $109.21 | 2019 | |
| Pfizer INC. | $107.94 | 2019 | |
| Medtronic, INC. | $88.69 | 2024 | Endo Gia Ultra |
| Astrazeneca Pharmaceuticals LP | $87.45 | 2019-2020 | |
| Novo Nordisk INC | $85.09 | 2019-2020 | |
| Genentech USA, INC. | $84.11 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.45 | 2019 | |
| Abbott Laboratories | $63.25 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $53.73 | 2019 | |
| Amarin Pharma, INC. | $36.35 | 2019 | |
| Supernus Pharmaceuticals, INC. | $34.77 | 2019 | |
| Lilly USA, LLC | $34.69 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $22.26 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $20.92 | 2019 | |
| Horizon Therapeutics Plc | $17.05 | 2019 | |
| Janssen Pharmaceuticals, INC | $15.77 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $15.14 | 2019 | |
| Alfasigma USA, INC. | $12.22 | 2020 | |
| Glaxosmithkline, LLC. | $11.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Byrum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.